Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile5 entries
2022
Boehringer Ingelheim sues Laurus over Jardiance patent
Lawsuit filed
Boehringer Ingelheim Pharmaceuticals and related entities filed a lawsuit against Laurus Labs and Laurus Generics in Delaware, alleging patent infringement related to a generic version of Jardiance and seeking injunctive relief and monetary damages.
Source excerpt
The plaintiff is suing for patent infringement and seeks declaratory judgment of infringement as well as injunctive relief preventing further infringement and monetary damages.
On Friday a case was filed in the District of Delaware by Boehringer Ingelheim Pharmaceuticals Inc., and related entities against Laurus Labs LTD and Laurus Generics Inc. The case is regarding patent infringement for the drug Jardiance.
2014
Pradaxa bleeding-injury litigation
The company agreed to a $650 million settlement involving approximately 3,900 claimants in U.S. litigation alleging severe bleeding events associated with Pradaxa.
2012
Off-label promotion settlement
Boehringer Ingelheim paid $95 million to resolve allegations concerning off-label promotion of several medicines and claims involving federal healthcare-program reimbursement.
2011
Ben Venue manufacturing and quality-control problems
U.S. regulatory inspectors reported serious conditions at the company’s Ben Venue facility, including corrosion, mold and an unidentified liquid later described as urine. The plant was voluntarily shut down, partially restarted after substantial investment and ultimately closed in 2013.
1954
Employment of convicted war criminal
Historical accounts state that the company employed Fritz Fischer after his release from prison. Fischer had been convicted at the Nuremberg trials for war crimes and crimes against humanity. The company’s wartime history and involvement in chemical supply are subjects of historical scrutiny.